IL5 and inflammatory bowel disease: From a clinical perspective, it suggests that in disease states with high IL-5 (like hypereosinophilic syndromes or active IBD with a type 2 skew), targeting Siglec-8 could be especially effective in depleting pathogenic eosinophils.